Expertise in
3
conditions

Eiju Negoro

Matsuoka, JP 
Expertise in
3
conditions
Matsuoka, JP 

Overview

Eiju Negoro practices practicing medicine in Matsuoka, Japan.

Negoro is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Lymphomatoid Granulomatosis.

They are actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Locations

Matsuoka, 9101193, Japan
Other Locations
Japan
Yoshida, 9101193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
View 1 Less Clinical Trial

43 Total Publications

Progressive Multifocal Leukoencephalopathy or Lymphoma? A Massive Unilateral Hemispheric Mimicker in a Patient Undergoing Lymphoma Treatment.
Progressive Multifocal Leukoencephalopathy or Lymphoma? A Massive Unilateral Hemispheric Mimicker in a Patient Undergoing Lymphoma Treatment.
Journal: Reports (MDPI)
Published: April 27, 2026

Frequently Asked Questions about Eiju Negoro

Is Eiju Negoro a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Eiju Negoro is classified as an Advanced expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eiju Negoro participate in research or clinical trials?

Yes. Eiju Negoro has published 43 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Eiju Negoro's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Negoro's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile